The Effect of Losartan on Atrial Fibrillation (AF) Burden and Pacemaker Dependence in Patients With Sick Sinus Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00647257|
Recruitment Status : Unknown
Verified March 2010 by Chung Shan Medical University.
Recruitment status was: Recruiting
First Posted : March 31, 2008
Last Update Posted : April 1, 2010
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation||Drug: Losartan Drug: Placebo||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||220 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The Effect of Losartan on Atrial Fibrillation and Pacemaker Dependence in Sick Sinus Syndrome (SSS) Patients Receiving Physiological Pacemaker - A Prospective, Randomized, Multicenter Study in Taiwan|
|Study Start Date :||April 2008|
|Estimated Primary Completion Date :||December 2008|
|Estimated Study Completion Date :||December 2009|
|Active Comparator: A||
Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
|Placebo Comparator: B||
Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
- The proportion of patients who developed AF burden by pacemaker telemetry and developed permanent AF [ Time Frame: 12-month study period(2-week + 2-week + 4-week + 4-week + 3-month + 3-month + 3-month) ]
- The time to first occurrence of AF lasting for at least 1 minute after pacemaker insertion, and the AF burden over time measured as the portion of AF per day (in hours/day) [ Time Frame: 12-month study period(2-week + 2-week + 4-week + 4-week + 3-month + 3-month + 3-month) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00647257
|Contact: Kwo-Chang Ueng, MD; PhDfirstname.lastname@example.org; email@example.com|
|Chung Shan Medical University Hospital||Recruiting|
|Taichung, Taiwan, 402|
|Contact: Kwo-Chang Ueng, MD; PhD 886-4-24739595 ext 38231 firstname.lastname@example.org; email@example.com|
|Principal Investigator: Kwo-Chang Ueng, MD; PhD|
|Principal Investigator:||Kwo-Chang Ueng, MD; PhD||Chung Shan Medical University|